Clinical pharmacokinetics of metformin.
Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusion through cell membranes should be very limited. The mean ± SD fractional oral bioavailability (F) of metformin is 55 ± 16%. It is absorbed predominately from the small intestine. Metformin is excreted unchanged in urine. The elimination half-life (t(&frac12;)) of metformin during multiple dosages in patients with good renal function is approximately 5 hours. From published data on the pharmacokinetics of metformin, the population mean of its clearances were calculated. The population mean renal clearance (CL(R)) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be 510 ± 130 mL/min and 1140 ± 330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function. Over a range of renal function, the population mean values of CL(R) and CL/F of metformin are 4.3 ± 1.5 and 10.7 ± 3.5 times as great, respectively, as the clearance of creatinine (CL(CR)). As the CL(R) and CL/F decrease approximately in proportion to CL(CR), the dosage of metformin should be reduced in patients with renal impairment in proportion to the reduced CL(CR). The oral absorption, hepatic uptake and renal excretion of metformin are mediated very largely by organic cation transporters (OCTs). An intron variant of OCT1 (single nucleotide polymorphism [SNP] rs622342) has been associated with a decreased effect on blood glucose in heterozygotes and a lack of effect of metformin on plasma glucose in homozygotes. An intron variant of multidrug and toxin extrusion transporter [MATE1] (G>A, SNP rs2289669) has also been associated with a small increase in antihyperglycaemic effect of metformin. Overall, the effect of structural variants of OCTs and other cation transporters on the pharmacokinetics of metformin appears small and the subsequent effects on clinical response are also limited. However, intersubject differences in the levels of expression of OCT1 and OCT3 in the liver are very large and may contribute more to the variations in the hepatic uptake and clinical effect of metformin. Lactic acidosis is the feared adverse effect of the biguanide drugs but its incidence is very low in patients treated with metformin. We suggest that the mean plasma concentrations of metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect.
Department of Pharmacology & Toxicology, St Vincents Clinical School, University of New South Wales, Sydney, New South Wales, Australia. g.graham@unsw.edu.au
Garry G
GG
Graham
Jeroen
J
Punt
Manit
M
Arora
Richard O
RO
Day
Matthew P
MP
Doogue
Janna K
JK
Duong
Timothy J
TJ
Furlong
Jerry R
JR
Greenfield
Louise C
LC
Greenup
Carl M
CM
Kirkpatrick
John E
JE
Ray
Peter
P
Timmins
Kenneth M
KM
Williams
D000284:Administration, Oral; D001682:Biological Availability; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007275:Injections, Intravenous; D008687:Metformin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D027701:Organic Cation Transport Proteins / Q000235:genetics* / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D051437:Renal Insufficiency / Q000378:metabolism
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D027701:Organic Cation Transport Proteins; D008687:Metformin
Clin Nutr. 2006 Aug;25(4):606-16
16698134
Diabetologia. 1969 Oct;5(5):318-24
5360810
Clin Pharmacol Ther. 1978 Dec;24(6):683-93
710026
J Clin Invest. 2007 May;117(5):1422-31
17476361
Br J Clin Pharmacol. 1981 Aug;12(2):235-46
7306436
J Clin Endocrinol Metab. 2010 Oct;95(10):E204-8
20660041
Prenat Diagn. 2008 Jun;28(6):544-8
18509858
Drug Metab Dispos. 2010 May;38(5):833-40
20118196
Diabetes. 2009 Jun;58(6):1434-9
19336679
Semin Dial. 2006 Jan-Feb;19(1):80-3
16423187
Ther Drug Monit. 2006 Feb;28(1):67-72
16418696
Diabetes. 2009 Mar;58(3):745-9
19228809
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1494-502
11185672
J Hum Genet. 2008;53(7):607-614
18414781
Pharmacol Toxicol. 2003 Aug;93(2):98-9
12899672
J Clin Pharmacol. 1995 Nov;35(11):1094-102
8626883
Drug Metab Dispos. 2007 Oct;35(10):1956-62
17600084
Am J Physiol Cell Physiol. 2006 Oct;291(4):C678-86
16641166
Mol Pharmacol. 2003 Apr;63(4):844-8
12644585
J Clin Pharmacol. 2008 Jun;48(6):696-707
18372428
J Clin Pharmacol. 2006 Feb;46(2):157-63
16432267
Drug Metab Dispos. 2007 Aug;35(8):1333-40
17496207
Diabetes Obes Metab. 2001 Jun;3(3):195-201
11412284
Drug Saf. 1994 Oct;11(4):223-41
7848543
Br J Clin Pharmacol. 2000 Oct;50(4):325-32
11012555
Biochem Pharmacol. 2007 Jul 15;74(2):359-71
17509534
Br J Clin Pharmacol. 1996 Oct;42(4):510-2
8904626
Drug Saf. 1999 Jun;20(6):489-503
10392666
Clin Pharmacol Ther. 2003 Jan;73(1):71-7
12545145
Diabetes Metab. 2003 Jun;29(3):279-83
12909816
Clin Pharmacol Ther. 2008 Feb;83(2):273-80
17609683
Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):337-48
19002438
Pharmacogenet Genomics. 2008 Jul;18(7):637-45
18551044
Diabetes Care. 2006 Apr;29(4):759-64
16567811
Diabetes Care. 2010 Jun;33(6):1291-3
20215446
Am J Emerg Med. 1997 Jan;15(1):107-8
9002594
J Pharm Pharm Sci. 2009;12(3):388-96
20067714
J Pharmacol Exp Ther. 2002 Aug;302(2):510-5
12130709
Clin Pharmacol Ther. 2009 Dec;86(6):595-8
19915604
Clin Pharmacokinet. 2005;44(7):721-9
15966755
Biopharm Drug Dispos. 2009 Nov;30(8):476-84
19768675
Diabetes Care. 2008 Nov;31(11):2086-91
18782901
Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967
20393934
Clin Pharmacol Ther. 2009 Sep;86(3):299-306
19536068
Br J Clin Pharmacol. 1979 Oct;8(4):372-3
41551
N Engl J Med. 2008 May 8;358(19):2003-15
18463376
Hepatology. 2009 Oct;50(4):1227-40
19591196
Diabet Med. 2006 Jun;23(6):579-93
16759299
Br J Clin Pharmacol. 1987 May;23(5):545-51
3593625
Neth J Med. 2008 May;66(5):185-90
18490795
Clin Pharmacokinet. 2007;46(8):623-44
17655371
Pharmacogenet Genomics. 2010 Feb;20(2):135-8
20016398
J Pharm Pharmacol. 1991 Jun;43(6):442-4
1681061
Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005
20053795
Nephron. 1976;16(1):31-41
1244564
Br J Pharmacol. 1994 Jun;112(2):671-5
8075887
Drug Metab Dispos. 2008 Aug;36(8):1650-8
18458049
Curr Med Res Opin. 2008 Jun;24(6):1703-9
18471347
J Pharmacol Exp Ther. 2010 Apr;333(1):341-50
20065018
Drug Metab Dispos. 2009 Mar;37(3):555-9
19074525
Drug Metab Pharmacokinet. 2008;23(4):243-53
18762711
Pharmacogenet Genomics. 2009 Jul;19(7):497-504
19483665
J Clin Pharmacol. 1996 Nov;36(11):1012-21
8973990
Am J Physiol Renal Physiol. 2009 Jun;296(6):F1307-13
19357181
Diabet Med. 2006 Mar;23(3):223-7
16492202
Pharmacogenet Genomics. 2010 Nov;20(11):687-99
20859243
J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127
7014827
Biochem Pharmacol. 2005 Dec 5;70(12):1851-60
16263091
J Clin Pharmacol. 2000 Nov;40(11):1280-5
11075314
Kidney Int. 2009 Apr;75(7):757-8
19282861
Eur J Clin Pharmacol. 1979 Sep;16(3):195-202
499320
Diabet Med. 1994 Dec;11(10):953-60
7895460
Diabetes Care. 2006 Aug;29(8):1963-72
16873813
Clin Ther. 2005 Oct;27(10):1596-606
16330295
Drug Saf. 1999 Apr;20(4):377-84
10230584
Clin Pharmacol Ther. 2008 Nov;84(5):559-62
18401339
Blood. 2007 Dec 1;110(12):4064-72
17761829
Diabetes. 2010 Oct;59(10):2672-81
20682687
Diabete Metab. 1990 Dec;16(6):473-8
2086278
Curr Med Res Opin. 2009 May;25(5):1265-72
19364302
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jul 1;854(1-2):91-8
17459785
Curr Med Res Opin. 2006 Oct;22(10):1939-47
17022853
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8
16330770
Curr Med Res Opin. 2008 Aug;24(8):2313-26
18786303
Drug Metabol Drug Interact. 2002;19(1):41-8
12222753
J Clin Pharmacol. 2007 Jan;47(1):48-55
17192501
Pharmacogenet Genomics. 2010 Jan;20(1):38-44
19898263
Obstet Gynecol. 2009 Jan;113(1):193-205
19104375
Diabet Med. 2006 Mar;23(3):323-6
16492218
Diabetologia. 2008 Aug;51(8):1552-3
18528677
Biopharm Drug Dispos. 2004 Sep;25(6):261-3
15334625
Pharmacogenomics J. 2009 Aug;9(4):242-7
19381165